Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardized inpatient hyperglycemia management pathway with intensive insulin regimen comparison
ChiCTR-IPR-15007487Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin aspart and insulin glargine in type 2 diabetes mellitus (T2DM) and hyperglycemia (3 arms), sponsored by Nanjing First Hospital. Primary endpoint: blood glucose. Started Dec 2015; status: recruiting.
02
Drugs
insulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)hyperglycemia
Beyond the preview
Go deeper on ChiCTR-IPR-15007487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007487.